DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 28.70% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 4.66B.
Undervalued
The company’s latest PE is 29.26, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 384.48M shares, decreasing 5.90% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.